[SCHEDULE 13G/A] Unicycive Therapeutics, Inc. SEC Filing
Octagon Capital Advisors LP and related funds and principal Ting Jia report beneficial ownership of 1,000,000 shares of Unicycive Therapeutics, Inc. (UNCY), representing 7.8% of the outstanding common stock based on 12,768,239 shares outstanding as reported by the issuer. Octagon is the investment manager of the funds and Mr. Jia is the managing member of Octagon, and by virtue of those relationships Octagon and Mr. Jia may be deemed to beneficially own the shares held by the funds.
The filing discloses that the reported holdings are held with shared voting and dispositive power rather than sole power. The ownership is allocated as 650,000 shares (5.1%) held by Octagon Investments Master Fund LP and 350,000 shares (2.7%) held by Octagon Private Opportunities Fund II LP. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Octagon Capital Advisors LP e i fondi correlati e il principale Ting Jia segnalano la propriet脿 beneficiaria di 1,000,000 azioni di Unicycive Therapeutics, Inc. (UNCY), pari al 7.8% del capitale sociale ordinario in circolazione sulla base di 12,768,239 azioni in circolazione come riportato dall'emittente. Octagon 猫 il gestore degli investimenti dei fondi e il sig. Jia 猫 il membro amministratore di Octagon; in virt霉 di tali rapporti Octagon e il sig. Jia possono essere ritenuti beneficiari delle azioni detenute dai fondi.
Il deposito indica che le partecipazioni dichiarate sono detenute con potere di voto e di disposizione condivisi e non con potere esclusivo. La propriet脿 猫 ripartita in 650,000 azioni (5.1%) detenute da Octagon Investments Master Fund LP e 350,000 azioni (2.7%) detenute da Octagon Private Opportunities Fund II LP. Il deposito include una certificazione che i titoli sono stati acquisiti e sono detenuti nell'ordinario corso dell'attivit脿 e non allo scopo di modificare o influenzare il controllo dell'emittente.
Octagon Capital Advisors LP y los fondos relacionados y el principal Ting Jia comunican la titularidad beneficiaria de 1,000,000 acciones de Unicycive Therapeutics, Inc. (UNCY), lo que representa el 7.8% del capital social ordinario en circulaci贸n, seg煤n las 12,768,239 acciones en circulaci贸n reportadas por el emisor. Octagon es el administrador de inversiones de los fondos y el Sr. Jia es el miembro gerente de Octagon; en virtud de esas relaciones, Octagon y el Sr. Jia pueden considerarse beneficiarios de las acciones que poseen los fondos.
La presentaci贸n revela que las participaciones declaradas se mantienen con poder compartido de voto y de disposici贸n y no con poder exclusivo. La propiedad se asigna como 650,000 acciones (5.1%) mantenidas por Octagon Investments Master Fund LP y 350,000 acciones (2.7%) mantenidas por Octagon Private Opportunities Fund II LP. La presentaci贸n incluye una certificaci贸n de que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control del emisor.
Octagon Capital Advisors LP 氚� 甏�霠� 韼�霌滌檧 雽�響滌瀽 Ting Jia電� Unicycive Therapeutics, Inc. (UNCY)鞚� 1,000,000欤检棎 雽�頃� 靾橃澋鞝� 靻岇湢甓岇潉 鞁犼碃頄堨溂氅�, 鞚措姅 氚滍枆鞛愱皜 氤搓碃頃� 12,768,239欤检潣 氚滍枆欤检嫕 旮办鞙茧 鞙犿喌 欷戩澑 氤错喌欤� 臧�鞖措嵃 7.8%鞐� 頃措嫻頃╇媹雼�. Octagon鞚� 頃措嫻 韼�霌滊摛鞚� 韴瀽鞖挫毄靷澊瓿� Jia 鞌姅 Octagon鞚� 毵る媹歆� 氅る矂搿�, 鞚措煬頃� 甏�瓿勳棎 霐半澕 Octagon瓿� Jia 鞌姅 韼�霌滉皜 氤挫湢頃� 欤检嫕鞚� 鞁れ鞝� 靻岇湢鞛愲 臧勳＜霅� 靾� 鞛堨姷雼堧嫟.
鞁犼碃靹滌棎電� 鞁犼碃霅� 氤挫湢欤检嫕鞚� 雼弲 甓岉暅鞚� 鞎勲媽 瓿惦彊鞚� 鞚橁舶甓� 氚� 觳橂秳甓�鞙茧 氤挫湢霅橃柎 鞛堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 靻岇湢 歆�攵勳潃 Octagon Investments Master Fund LP臧� 氤挫湢頃� 650,000欤�(5.1%)鞕� Octagon Private Opportunities Fund II LP臧� 氤挫湢頃� 350,000欤�(2.7%)搿� 氚半秳霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃靹滌棎電� 頃措嫻 歃濌秾鞚� 鞓侅梾鞚� 韱奠儊鞝侅澑 氩旍渼鞐愳劀 旆摑路氤挫湢霅橃棃鞙茧┌ 氚滍枆靷潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃� 氇╈爜鞙茧 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Octagon Capital Advisors LP et des fonds associ茅s ainsi que le principal Ting Jia d茅clarent la propri茅t茅 b茅n茅ficiaire de 1,000,000 actions de Unicycive Therapeutics, Inc. (UNCY), repr茅sentant 7.8% du capital social ordinaire en circulation sur la base de 12,768,239 actions en circulation rapport茅es par l'茅metteur. Octagon est le gestionnaire d'investissement des fonds et M. Jia est le membre directeur d'Octagon ; en vertu de ces relations, Octagon et M. Jia peuvent 锚tre consid茅r茅s comme b茅n茅ficiant de la propri茅t茅 des actions d茅tenues par les fonds.
Le d茅p么t indique que les participations d茅clar茅es sont d茅tenues avec un pouvoir de vote et de disposition partag茅 plut么t qu'un pouvoir exclusif. La d茅tention se r茅partit comme suit : 650,000 actions (5.1%) d茅tenues par Octagon Investments Master Fund LP et 350,000 actions (2.7%) d茅tenues par Octagon Private Opportunities Fund II LP. Le d茅p么t inclut une certification selon laquelle les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Octagon Capital Advisors LP und verbundene Fonds sowie der Principal Ting Jia melden wirtschaftliches Eigentum an 1,000,000 Aktien von Unicycive Therapeutics, Inc. (UNCY), was gem盲脽 den vom Emittenten gemeldeten 12,768,239 ausstehenden Aktien 7.8% des ausstehenden Stammkapitals entspricht. Octagon ist der Investmentmanager der Fonds und Herr Jia ist gesch盲ftsf眉hrendes Mitglied von Octagon; aufgrund dieser Beziehungen k枚nnen Octagon und Herr Jia als wirtschaftliche Eigent眉mer der von den Fonds gehaltenen Aktien angesehen werden.
Die Einreichung legt offen, dass die gemeldeten Best盲nde mit gemeinsamen Stimm- und Verf眉gungsrechten und nicht mit alleinigem Recht gehalten werden. Die Beteiligung ist wie folgt aufgeteilt: 650,000 Aktien (5.1%) werden von Octagon Investments Master Fund LP gehalten und 350,000 Aktien (2.7%) werden von Octagon Private Opportunities Fund II LP gehalten. Die Einreichung enth盲lt eine Best盲tigung, dass die Wertpapiere im normalen Gesch盲ftsverlauf erworben und gehalten wurden und nicht zum Zweck der 脛nderung oder Beeinflussung der Kontrolle des Emittenten dienen.
- Material disclosure: A combined stake of 1,000,000 shares equals 7.8% of UNCY, exceeding the 5% reporting threshold.
- Clear allocation: Holdings are broken down by fund: 650,000 shares (5.1%) for the Master Fund and 350,000 shares (2.7%) for Private Fund II, improving transparency.
- No sole control: All reported voting and dispositive powers are shared (sole power reported as 0), indicating no direct control by the reporting persons.
- Held on behalf of investors: The funds hold the shares for their investors, meaning the economic interest is indirect rather than personal.
Insights
TL;DR Octagon and affiliates hold 7.8% of UNCY through funds, a material stake that signals investor interest but not control.
The Schedule 13G/A shows a combined beneficial ownership of 1,000,000 shares, equal to 7.8% of the outstanding common stock based on 12,768,239 shares. The reporting structure is fund-centric: 650,000 shares are held by the Master Fund and 350,000 by Private Fund II, with Octagon acting as investment manager and Mr. Jia as managing member. All voting and dispositive powers disclosed are shared rather than sole, which means the position is meaningful but does not convey direct control. The filing also affirms acquisition in the ordinary course of business.
TL;DR A >5% aggregated holding is reportable and material; governance impact appears limited because power is shared and not sole.
The document identifies joint filing by Octagon entities and Ting Jia and discloses shared voting and dispositive power for the reported positions. Because the reporting persons disclaim sole voting power, the stake is significant under disclosure rules but does not indicate an expressed intent to change board composition or control. The certification attesting ordinary-course acquisition further supports a passive, disclosure-driven filing rather than an activist posture.
Octagon Capital Advisors LP e i fondi correlati e il principale Ting Jia segnalano la propriet脿 beneficiaria di 1,000,000 azioni di Unicycive Therapeutics, Inc. (UNCY), pari al 7.8% del capitale sociale ordinario in circolazione sulla base di 12,768,239 azioni in circolazione come riportato dall'emittente. Octagon 猫 il gestore degli investimenti dei fondi e il sig. Jia 猫 il membro amministratore di Octagon; in virt霉 di tali rapporti Octagon e il sig. Jia possono essere ritenuti beneficiari delle azioni detenute dai fondi.
Il deposito indica che le partecipazioni dichiarate sono detenute con potere di voto e di disposizione condivisi e non con potere esclusivo. La propriet脿 猫 ripartita in 650,000 azioni (5.1%) detenute da Octagon Investments Master Fund LP e 350,000 azioni (2.7%) detenute da Octagon Private Opportunities Fund II LP. Il deposito include una certificazione che i titoli sono stati acquisiti e sono detenuti nell'ordinario corso dell'attivit脿 e non allo scopo di modificare o influenzare il controllo dell'emittente.
Octagon Capital Advisors LP y los fondos relacionados y el principal Ting Jia comunican la titularidad beneficiaria de 1,000,000 acciones de Unicycive Therapeutics, Inc. (UNCY), lo que representa el 7.8% del capital social ordinario en circulaci贸n, seg煤n las 12,768,239 acciones en circulaci贸n reportadas por el emisor. Octagon es el administrador de inversiones de los fondos y el Sr. Jia es el miembro gerente de Octagon; en virtud de esas relaciones, Octagon y el Sr. Jia pueden considerarse beneficiarios de las acciones que poseen los fondos.
La presentaci贸n revela que las participaciones declaradas se mantienen con poder compartido de voto y de disposici贸n y no con poder exclusivo. La propiedad se asigna como 650,000 acciones (5.1%) mantenidas por Octagon Investments Master Fund LP y 350,000 acciones (2.7%) mantenidas por Octagon Private Opportunities Fund II LP. La presentaci贸n incluye una certificaci贸n de que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control del emisor.
Octagon Capital Advisors LP 氚� 甏�霠� 韼�霌滌檧 雽�響滌瀽 Ting Jia電� Unicycive Therapeutics, Inc. (UNCY)鞚� 1,000,000欤检棎 雽�頃� 靾橃澋鞝� 靻岇湢甓岇潉 鞁犼碃頄堨溂氅�, 鞚措姅 氚滍枆鞛愱皜 氤搓碃頃� 12,768,239欤检潣 氚滍枆欤检嫕 旮办鞙茧 鞙犿喌 欷戩澑 氤错喌欤� 臧�鞖措嵃 7.8%鞐� 頃措嫻頃╇媹雼�. Octagon鞚� 頃措嫻 韼�霌滊摛鞚� 韴瀽鞖挫毄靷澊瓿� Jia 鞌姅 Octagon鞚� 毵る媹歆� 氅る矂搿�, 鞚措煬頃� 甏�瓿勳棎 霐半澕 Octagon瓿� Jia 鞌姅 韼�霌滉皜 氤挫湢頃� 欤检嫕鞚� 鞁れ鞝� 靻岇湢鞛愲 臧勳＜霅� 靾� 鞛堨姷雼堧嫟.
鞁犼碃靹滌棎電� 鞁犼碃霅� 氤挫湢欤检嫕鞚� 雼弲 甓岉暅鞚� 鞎勲媽 瓿惦彊鞚� 鞚橁舶甓� 氚� 觳橂秳甓�鞙茧 氤挫湢霅橃柎 鞛堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 靻岇湢 歆�攵勳潃 Octagon Investments Master Fund LP臧� 氤挫湢頃� 650,000欤�(5.1%)鞕� Octagon Private Opportunities Fund II LP臧� 氤挫湢頃� 350,000欤�(2.7%)搿� 氚半秳霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃靹滌棎電� 頃措嫻 歃濌秾鞚� 鞓侅梾鞚� 韱奠儊鞝侅澑 氩旍渼鞐愳劀 旆摑路氤挫湢霅橃棃鞙茧┌ 氚滍枆靷潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃� 氇╈爜鞙茧 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Octagon Capital Advisors LP et des fonds associ茅s ainsi que le principal Ting Jia d茅clarent la propri茅t茅 b茅n茅ficiaire de 1,000,000 actions de Unicycive Therapeutics, Inc. (UNCY), repr茅sentant 7.8% du capital social ordinaire en circulation sur la base de 12,768,239 actions en circulation rapport茅es par l'茅metteur. Octagon est le gestionnaire d'investissement des fonds et M. Jia est le membre directeur d'Octagon ; en vertu de ces relations, Octagon et M. Jia peuvent 锚tre consid茅r茅s comme b茅n茅ficiant de la propri茅t茅 des actions d茅tenues par les fonds.
Le d茅p么t indique que les participations d茅clar茅es sont d茅tenues avec un pouvoir de vote et de disposition partag茅 plut么t qu'un pouvoir exclusif. La d茅tention se r茅partit comme suit : 650,000 actions (5.1%) d茅tenues par Octagon Investments Master Fund LP et 350,000 actions (2.7%) d茅tenues par Octagon Private Opportunities Fund II LP. Le d茅p么t inclut une certification selon laquelle les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Octagon Capital Advisors LP und verbundene Fonds sowie der Principal Ting Jia melden wirtschaftliches Eigentum an 1,000,000 Aktien von Unicycive Therapeutics, Inc. (UNCY), was gem盲脽 den vom Emittenten gemeldeten 12,768,239 ausstehenden Aktien 7.8% des ausstehenden Stammkapitals entspricht. Octagon ist der Investmentmanager der Fonds und Herr Jia ist gesch盲ftsf眉hrendes Mitglied von Octagon; aufgrund dieser Beziehungen k枚nnen Octagon und Herr Jia als wirtschaftliche Eigent眉mer der von den Fonds gehaltenen Aktien angesehen werden.
Die Einreichung legt offen, dass die gemeldeten Best盲nde mit gemeinsamen Stimm- und Verf眉gungsrechten und nicht mit alleinigem Recht gehalten werden. Die Beteiligung ist wie folgt aufgeteilt: 650,000 Aktien (5.1%) werden von Octagon Investments Master Fund LP gehalten und 350,000 Aktien (2.7%) werden von Octagon Private Opportunities Fund II LP gehalten. Die Einreichung enth盲lt eine Best盲tigung, dass die Wertpapiere im normalen Gesch盲ftsverlauf erworben und gehalten wurden und nicht zum Zweck der 脛nderung oder Beeinflussung der Kontrolle des Emittenten dienen.
FAQ
How many Unicycive (UNCY) shares do Octagon and affiliates report owning?
What is the breakdown of the 1,000,000 shares reported for UNCY?
Do the reporting persons have sole voting or dispositive power over the UNCY shares?
Was the UNCY position acquired to influence control of the company?
On what share count is the 7.8% figure based for UNCY?
